Concord Medical Services Reports First-Half 2025 Revenue Down 8.3% to RMB200.6 Million; Hospital Business Revenue Up 11.1%, Network Business Revenue Down 41.3%
Reuters
Sep 26
Concord Medical Services Reports First-Half 2025 Revenue Down 8.3% to RMB200.6 Million; Hospital Business Revenue Up 11.1%, Network Business Revenue Down 41.3%
Concord Medical Services Holdings Limited reported total net revenues of RMB200.6 million (US$28.0 million) for the first half of 2025, reflecting an 8.3% decrease compared to RMB218.8 million in the same period of 2024. The hospital business recorded net revenues of RMB153.0 million (US$21.4 million), up 11.1% from RMB137.8 million in the first half of 2024, primarily attributed to the commencement of proton therapy operations at Guangzhou Concord Cancer Hospital. The network business reported net revenues of RMB47.6 million (US$6.6 million), down 41.3% from RMB81.0 million in the prior-year period, mainly due to decreased demand for medical equipment and software. Gross loss from operating business amounted to RMB4.3 million (US$0.6 million), compared to RMB41.6 million in the first half of 2024. The gross loss margin was 2.1%, compared to 19.0% in the same period last year, which the company attributed to changes in revenue structure and efficiency improvements related to the launch of proton therapy services. The company highlighted the expansion of its hospital business and the start of proton therapy operations at Guangzhou Concord Cancer Hospital as significant operational developments during the reporting period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CMS - Concord Medical Services Holdings Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN84173) on September 26, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.